Significance, management and prevention of Streptococcus agalactiae infection during the perinatal period

References

• Baker CJ, Barrett FF, Gordon RC, Yow MD. Suppurative meningitis due to streptococci of Lancefield group B: a study of 33 infants. J. Pediatr. 82, 724–729 (1973).
   PubMed Web of Science ®Google Scholar
• Barton LL, Feigin RD, Lins R. Group B 0-hemolytic streptococcal meningitis in infants. J. Pediatr. 82,719–723 (1973).
   PubMed Web of Science ®Google Scholar
• Franciosi RA, Knostman JD, Zimmerman RA. Group B streptococcal neonatal and infant infections. J. Pediatr. 82,707–718 (1973).
   PubMed Web of Science ®Google Scholar
• Heath PT, Balfour G, Weisner AM, et al. Group B streptococcal disease in UK andIrish infants younger than 90 days. Lancet 363,292–294 (2004).
   PubMed Web of Science ®Google Scholar
• •• Very recent, very interesting and very comprehensive paper on the incidence and epidemiology of group B streptococcus (GBS) infection in a country outside the USA.
   Google Scholar
• Zaleznik DF, Rench MA, Hillier S, et al. Invasive disease due to group B streptococcus in pregnant women and neonates from diverse populations. Clin. Infect. Dis. 30,276–281 (2000).
   PubMed Web of Science ®Google Scholar
• Baltimore RS, Huie SM, Meek JI, et al. Early onset neonatal sepsis in the era of group B streptococcal prevention.Pediatrics 108,1094–1098 (2001).
   PubMed Web of Science ®Google Scholar
• Schrag SJ, Zywicki S, Farley MM, et al. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N EngL J. Med. 342,15–20 (2000).
   PubMed Web of Science ®Google Scholar
• Schuchat A, Zywicki SS, Dinsmoor MJ, et al. Risk factors and opportunities for prevention of early onset neonatal sepsis. A multicenter case-control study. Pediatrics 105,21–26 (2000).
   PubMed Web of Science ®Google Scholar
• Berner R. Group B streptococci in pregnancy and infancy. Curr. Opin. Infect. Dis. 15,307–313 (2002).
   PubMed Web of Science ®Google Scholar
• Davies HD, Raj S, Adair C, et al. Population-based active surveillance for neonatal group B streptococcal infections in Alberta, Canada: implications for vaccine formulation. Pediatr. Infect. Dis. J. 20,879–884 (2001).
   PubMed Web of Science ®Google Scholar
• Manning SD, Pearlman ME, Tallman P, et al. Frequency of antibiotic resistance among group B streptococcus isolated from healthy college students. Clin. Infect. Dis. 33, e17—e139 (2001).
   Web of Science ®Google Scholar
• Schuchat A. Epidemiology of Group B streptococcal disease in the United States: shifting paradigms. Clin. Microbial Rev. 11,497–513 (1998).
   PubMed Web of Science ®Google Scholar
• Farley MM. Group B streptococcal disease in nonpregnant adults. Clin. Infect. Dis. 33,556–561 (2001).
   PubMed Web of Science ®Google Scholar
• Davies HD, Adair C, McGeer A, et al. Antibodies to capsular polysaccharides of group B streptococcus in pregnant Canadian women: relationship to colonization status and infection in the neonate. J. Infect. Dis. 184,285–291 (2001).
   PubMed Web of Science ®Google Scholar
• Berner R, Bender A, Rensing C, Forster J, Brandis M. Low prevalence of the immunoglobulin A binding 0-antigen of the C protein among Streptococcus agalactiae isolates causing neonatal sepsis. Eur. J. Clin. Microbial Infect. Dis.18, 545–550 (1999).
   Google Scholar
• Rubens CE, Wessels MR, Heggen LM, Kasper DL. Transposon mutagenesis of Type III group B streptococcus: correlation of capsule expression with virulence. Proc. Nati Acad. Sci. USA 84, 7208–7212 (1987).
   PubMed Web of Science ®Google Scholar
• Musser JM, Mattingly SJ, Quentin R, et al. Identification of a high-virulence clone of Type III Streptococcus agalactiae (group B streptococcus) causing invasive neonatal disease. Proc. Nati Acad. Sci. USA 86,4731–4735 (1989).
   PubMed Web of Science ®Google Scholar
• Bohnsack JF, Takahashi S, Detrick SR, et al. Phylogenetic classification of serotype III group B streptococci on the basis of hylB gene analysis and DNA sequences specific to restriction digest pattern Type 111. 1. Infect. Dis. 183, 1694–1697 (2001).
   Google Scholar
• Bohnsack JF, Whiting AA, Bradford RD, et al. Long-range mapping of the Streptococcus agalactiae phylogenetic lineage restriction digest pattern Type III reveals clustering of virulence genes. Infect. Immun. 70,134–139 (2002).
   PubMed Web of Science ®Google Scholar
• Bidet P, Brahimi N, Chalas C, Aujard Y, Bingen E. Molecular characterization of serotype III group B streptococcus isolates causing neonatal meningitis. J. Infect. Dis. 188,1132–1137 (2003).
   PubMed Web of Science ®Google Scholar
• Berner R, Csorba J, Brandis M. Different cytokine expression in cordblood mononuclear cells (CBMNC) after stimulation with neonatal sepsis or colonizing strains of Streptococcus agalactiae. Pediatr. Res. 49,691–697 (2001).
   PubMed Web of Science ®Google Scholar
• Adderson EE, Takahashi S, Wang Y, Armstrong J, Miller DV, Bohnsack JF. Subtractive hybridization identifies a novel predicted protein mediating epithelial cell invasion by virulent serotype III group B streptococcus agalactiae. Infect. Immun. 71, 6857–6863 (2003).
   PubMed Web of Science ®Google Scholar
• •Very interesting paper describing a genetic approach for identifying genes that might differentiate virulent from less-virulent GBS isolates.
   Google Scholar
• Tettelin H, Masignanin V, Cieslewicz MJ, et al. Complete genome sequence and comparative genomic analysis of an emerging human pathogen, serotype V Streptococcus agalactiae. Proc. Nati Acad. Sci. USA 99,12391–12396 (2002).
   PubMed Web of Science ®Google Scholar
• ••Key paper revealing the genomicsequence of GBS serotype V and comparing the genome with that of Streptococcus pneumonicte and Streptococcus pyogenes.
   Google Scholar
• Glaser P, Rusniok C, Buchrieser C, et al. Genome sequence of Streptococcus agalactiae, a pathogen causing invasive neonatal disease. Mal. Microbial 45, 1499–1513 (2002).
   PubMed Web of Science ®Google Scholar
• ••Second key paper on the completegenome analysis of GBS, this time of serotype III, revealing several pathogenicity islands within the genome.
   Google Scholar
• Von Both U, Ruess M, Mueller U, Fluegge K, Sander A, Berner R. A serotype V clone is predominant among erythromycin resistant Streptococcus agalactiae isolates in a south-western region of Germany. J. Clin. Microbial 41, 2166–2169 (2003).
   PubMed Web of Science ®Google Scholar
• Franken C, Haase G, Brandt C, et al. Horizontal gene transfer and host specificity of 0-haemolytic streptococci: the role of a putative composite transposon containing scpB and lmb. Mal. Microbial 41,925–935 (2001).
   PubMed Web of Science ®Google Scholar
• Doran SK, Liu GY, Nizet V. Group B streptococcal 0-hemolysin/cytolysin activates neutrophil signaling pathways in brain endothelium and contributes to development of meningitis. J. Clin. Invest. 112,736–744 (2003).
   PubMed Web of Science ®Google Scholar
• •Excellent paper reporting on the initial response of the blood—brain barrier to the B-hemolysin/cytolysin and the capsular polysaccharides of GBS.
   Google Scholar
• Harris TO, Shelver DW, Bohnsack JF, Rubens CE. A novel streptococcal surface protease promotes virulence, resistance to opsonophagocytosis and cleavage of human fibrinogen. J. Clin. Invest. 111,61–70 (2003).
   PubMed Web of Science ®Google Scholar
• •Innovative paper describing a new surface protein of GBS associated with virulence by protecting the bacterium from opsonophagocytosis and by cleavage of fibrinogen.
   Google Scholar
• Jones AL, Neeeham RHV, Clancy A, Knoll KM, Rubens CE. Penicillin-binding proteins in Streptococcus agalactiae a novel mechanism for evasion of immune clearance. Mal Microbial 47,247–256 (2003).
   PubMed Web of Science ®Google Scholar
• •Very fascinating study investigating the role of a penicillin-binding protein of GBS on evading the host's immune response.
   Google Scholar
• Jarya H, Hellwage J, Sakaari Jokiranta T, Lehtinen MJ, Zipfel PF, Men S. The group B streptococcal-0 and pneumococcal-Hic proteins are structurally related immune evasion molecules that bind the complement inhibitor factor H in an analogous fashion. J. Immunol 172, 3111–3118 (2004).
   PubMed Web of Science ®Google Scholar
• Doran KS, Chang JCW, Benoit VM, Eckmann L, Nizet V. Group B streptococcal 0-hemolysin/cytolysin promotes invasion of human lung epithelial cells and release of interleukin-8. J. Infect. Dis. 185,196–203 (2002).
   PubMed Web of Science ®Google Scholar
• Berner R, Niemeyer CM, Leititis JU, et al. Plasma levels and gene-expression of G-CSF,IL-10, IL-6, IL-8 andsICAM-1 in neonatal early onset sepsis. Pediatr. Res. 44,469–477 (1998).
   PubMed Web of Science ®Google Scholar
• Berner R, Fuerll B, Stelter F, Droese J, Mueller HP, Schuett C. Elevated plasma levels of lipopolysaccharide binding protein (LBP) and soluble CD14 in neonatal early onset sepsis. Clin. Diagn. Lab. Immunol 9, 440–445 (2002).
   PubMedGoogle Scholar
• Teti G, Mancuso G, Tomasello F. Cytokine appearance and effects of antitumor necrosis factor antibodies in a neonatal rat model of group B streptococcal infection. Infect. Immun. 61,227–232 (1993).
   PubMed Web of Science ®Google Scholar
• Joyner JL, Augustine NH, Taylor KA, La Pine RT, Hill HR. Effects of Group B streptococci on cord and adult mononuclear cell interleukin12 and interferon-y mRNA accumulation and protein secretion. J. Infect. Dis. 182, 974–977 (2000).
   PubMed Web of Science ®Google Scholar
• Cusumano V, Mancuso G, Genovese F, et al. Role of y-interferon in neonatal mouse model of group B streptococcal disease. Infect. Immun. 64,2941–2944 (1996).
   PubMed Web of Science ®Google Scholar
• Mancuso G, Cusumano V, Genovese F, et al. Role of interleukin-12 in experimental neonatal sepsis caused by group B streptococci. Infect. Immun. 65, 3731–3725 (1997).
   PubMed Web of Science ®Google Scholar
• Cusumano V, Midiri A, Cusumano VV, et al. Interleukin-18 is an essential element in host resistance to experimental group B streptococcal disease in neonates. Infect. Immun. 72,295–300 (2004).
   PubMed Web of Science ®Google Scholar
• •Interesting study investigating the role of interleukin (IL)-18 in a neonatal murine model of GBS disease and indicating a potential role of recombinant IL-18 for treatment of GBS infection.
   Google Scholar
• Medvedev AE, Flo T, Ingalls RR, et al. Involvement of CD14 and complement receptors CR3 and CR4 in nuclear factor-KB activation and TNF production induced by lipopolysaccharide and group B streptococcal cell walls. J. Immunol. 160,4535–4542 (1998).
   PubMed Web of Science ®Google Scholar
• Berner R, Welter P, Brandis M. Cytokine expression of cord and adult blood mononuclear cells in response to Streptococcus agalactiae. Pediatr. Res. 51, 304–309 (2002).
   PubMed Web of Science ®Google Scholar
• Henneke P0, Malley R, Takeuchi , et al . Cellular activation, phagocytosis and bactericidal activity against group B streptococcus involve parallel myeloid differentiation factor 88-dependent and independent signaling pathways. J. Immunol. 169,3970–3977 (2002).
   PubMed Web of Science ®Google Scholar
• •Interesting paper investigating the intracellular signaling pathways of the innate immune response to GBS.
   Google Scholar
• Cuzzola M, Mancuso G, Beninati C, et al. Human monocyte receptors involved in tumor necrosis factor responses to group B streptococcal products. Infect. Immun. 68,994–998 (2000).
   PubMed Web of Science ®Google Scholar
• Henneke P0, van Strijp JA , Takeuchi , et al . Novel engagement of CD14 and multiple Toll-like receptors by group B streptococci. J. Immunol. 167,7069–7076 (2001).
   PubMed Web of Science ®Google Scholar
• •Very important research investigating the role of the innate immune response to GBS, elucidating the role of a novel released heat-labile soluble factor of GBS.
   Google Scholar
• Centers for Disease Control and Prevention. Prevention of perinatal group B streptococcal disease. Morbid. Mortal. Wkly. Rep. 51 (RR-11), 1–24 (2002).
   Google Scholar
• •• Revised US Centers for Disease Control and Prevention (CDC) guidelines giving an excellent overview on the evidence and reasons for intrapartum antibiotic prophylaxis (TAP).
   Google Scholar
• Votava M, Tejkalová M, Drábková M, et al. Use of GBS media for rapid detection of group B streptococci in vaginal and rectal swabs from women in labor. Eur. J. Clin. Microbial. Infect. Dis. 20,120–122 (2001).
   PubMed Web of Science ®Google Scholar
• Park CH, Vandel NM, Ruprai DK, et al. Detection of group B streptococcal colonization in pregnant women using direct latex agglutination testing of selective broth. J. Clin. Microbial. 39, 408–409 (2001).
   PubMed Web of Science ®Google Scholar
• Podbielski A, Blankenstein P, Liitticken R. Molecular charaterization of the cfb gene encoding group B streptococcal CAMP-factor. Med. Microbial. Immunol. 183, 239–256 (1994).
   PubMed Web of Science ®Google Scholar
• Bergeron MG, Ke D, Menard C, et al. Rapid detection of group B streptococci in pregnant women at delivery. N Engl. J. Med. 343,175–179 (2000).
   PubMed Web of Science ®Google Scholar
• Schrag SJ, Zell ER, Lynfield R, et al. A population-based comparison of strategies to prevent early onset group B streptococcal disease in neonates. N Engl. J. Med. 347,233–239 (2002).
   PubMed Web of Science ®Google Scholar
• ••Very important multistate cohort studycomparing the effectiveness of the screening and risk-based approaches of TAP in preventing early onset GBS disease.
   Google Scholar
• Davies RL, Hasselquist MB, Cardenas V, et al. Introduction of the new Centers for Disease Control and Prevention group B streptococcal prevention guideline at a large West Coast health maintenance organization. Am. J. Obstet. Gynecol. 184, 603–610 (2001).
   PubMed Web of Science ®Google Scholar
• Towers CV, Carr MH, Padilla G, Asrat T. Potential consequences of widespread antepartal use of ampicillin. Am. J. Obstet. Gynecol. 179,879–883 (1998).
   PubMed Web of Science ®Google Scholar
• Byington CL, Rittichier KK, Bassett KE, et al. Serious bacterial infections in febrile infants younger than 90 days of age: the importance of ampicillin-resistant pathogens. Pediatrics 111,964–968 (2003).
   PubMed Web of Science ®Google Scholar
• Stoll BJ, Hansen N, Fanaroff AA, et al. Changes in pathogens causing early onset sepsis in very-low-birth-weight infants. N Engl. J. Med. 347,240–247 (2002).
   PubMed Web of Science ®Google Scholar
• ••Compares the distribution of microbescausing early onset sepsis among very-low-birth-weight infants before and after the widespread use of TAP.
   Google Scholar
• Hyde TB, Hilger TM, Reingold A, et al. Trends in incidence and antimicrobial resistance of early onset sepsis: population-based surveillance in San Francisco and Atlanta. Pediatrics 110, 690–695 (2002).
   PubMed Web of Science ®Google Scholar
• Isaacs D, Royle JA. Intrapartum antibiotics and early onset neonatal sepsis caused by group B streptococcus and by other organisms in Australia. Australasian Study Group for Neonatal Infections. Pediatr. Infect. Dis. J. 18,524–528 (1999).
   PubMed Web of Science ®Google Scholar
• Chen KT, Tuomala RE, Cohen AP, et al. No increase in rates of early onset neonatal sepsis by non-group B streptococcus or ampicillin-resistant organisms. Am. J. Obstet. Gynecol. 185, 854–858 (2001).
   Google Scholar
• Jakobi P, Sujov P, Itskovitz-Eldor J , Goldstick. New CDC guidelines for prevention of perinatal group B streptococcal disease. Lancet 361,351 (2003).
   PubMed Web of Science ®Google Scholar
• •Important contribution in a letter to the Editor strengthening the fact that the CDC guidelines might not be appropriate for all parts of the world.
   Google Scholar
• Bedford-Russell AR, Breathnach A, Sender P Confirmed group B streptococcus infections: the tip of the iceberg. Arch. Dis. Child. Fetal Neonatal Ed. 84, F140 (2001).
   Web of Science ®Google Scholar
• Luck S, Torny M, d'Agapeyeff K, et al. Estimated early onset group B streptococcal neonatal disease. Lancet 361, 1953–1954 (2003).
   PubMed Web of Science ®Google Scholar
• •Very interesting paper from the UK comparing the rate of definite and probable early onset GBS infection indicating a much greater disease burden than previously estimated.
   Google Scholar
• Regan JA, Klebanoff MA, Nugent RP, et al. Colonization with group B streptococci in pregnany and adverse outcome. Am. J. Obstet. Gynecol. 174, 1354–1360 (1996).
   PubMed Web of Science ®Google Scholar
• Feikin DR, Thorsan P, Zywicki S, et al. Association between colonization with group B streptococci during pregnancy and preterm delivery among Danish women. Am. J. Obstet. Gynecol. 184, 427–433 (2001).
   PubMed Web of Science ®Google Scholar
• De Azavedo JCS, McGavin M, Duncan C, et al. Prevalence and mechanisms of macrolide resistance in invasive and noninvasive group B streptococcus isolates from Ontario, Canada. Antimicrob. Agents Chemother. 45,3504–3508 (2001).
   PubMed Web of Science ®Google Scholar
• De Mouy D, Cavallo JD, Leclercq R, et al. Antibiotic susceptibility and mechanisms of erythromycin resistance in dincal isolates of Streptococcus agalactiae: a French multicenter study. Antimicrob. Agents Chemother. 45,2400–2402 (2001).
   PubMed Web of Science ®Google Scholar
• Ruess M, Mueller U, Sander A, Berner R. Antibiotic susceptibility pattern in Streptococcus agalactiae isolates in a German university hospital. Scand. J. Infect. Dis. 32,623–626 (2000).
   PubMed Web of Science ®Google Scholar
• Murdoch DR, Re11 LB. Antimicrobial susceptibilities of group B streptococci isolated from patients with invasive disease: 10-year perspective. Antimicrob. Agents Chemother. 45,3623–3624 (2001).
   PubMed Web of Science ®Google Scholar
• Fitoussi F, Loukil C, Gros I, et al. Mechanism of macrolide resistance in clinical group B streptococci isolated in France. Antimicrob. Agents Chemother. 45, 1889–1891 (2001).
   PubMed Web of Science ®Google Scholar
• Le Clercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance element and their clinical implications. Clin. Infect. Dis. 34, 482–492 (2002).
   PubMed Web of Science ®Google Scholar
• Uh Y, Jang ICH, Hwang GY, et al. Emerging erythromycin resistance among group B streptococci in Korea. Eur. J. Clin. Microbial Infect. Dis. 20,52–54 (2001).
   PubMed Web of Science ®Google Scholar
• Diekema DJ, Andrews JI, Huynh H, et al. Molecular epidemiology of macrolide resistance in neonatal bloodstream isolates of group B streptococci. J. Clin. Microbial 41,2659–2661 (2003).
   PubMed Web of Science ®Google Scholar
• Croak A, Abate G, Goodrum K, Modrzakowski M. Predominance of serotype V and frequency of erythromycin resistance in Streptococcus agalactiae in Ohio. Am. J. Obstet. Gynecol 188,1148–1150 (2003).
   PubMed Web of Science ®Google Scholar
• Poyart C, Jardy L, Quesne G, Berche P, Trieut-Cuot P. Genetic basis of antibiotic resistance in Streptococcus agalactiae strains isolated in a French hospital. Antimicrob. Agents Chemother. 47, 794–797 (2003).
   PubMed Web of Science ®Google Scholar
• Kawamura Y, Fujiwara H, Mishima N, et al. First Streptococcus agalactiae isolates highly resistant to quinolones with point mutations in gyrA and parC. Antimicrob. Agents Chemother. 47,3605–3609 (2003).
   PubMed Web of Science ®Google Scholar
• Fernandez M, Rench MA, Albanyan EA, et al. Failure of rifampin to eradicate group B streptococcal colonization in infants. Pediatr. Infect. Dis. J. 20,371–376 (2001).
   PubMed Web of Science ®Google Scholar
• Baker CJ, Rench MA, McInnes P. Immunization of pregnant women with group B streptococcus Type III capsular polysaccharide—tetanus toxoid conjugate vaccine. Vaccine 21,3468–3472 (2003).
   PubMed Web of Science ®Google Scholar
• •Interesting study determining the safety and immunogenicity of GBS Type III capsular polysaccharides—tetanus toxoid conjugate vaccine in pregnant women.
   Google Scholar
• Schuchat A. Group B streptococcus. Lancet 353,51–56 (1999).
   PubMed Web of Science ®Google Scholar
• Baker CJ, Kasper DL. Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl. J. Med. 294,753–756 (1976).
   PubMed Web of Science ®Google Scholar
• Lin FY, Phillips JB III, Azimi PH, et al. Level of maternal antibody required to protect neonates against early onset disease caused by group B streptococcus Type Ia: a multicenter, seroepidemiology study. J. Infect. Dis. 184,1022-1028 (2001).
   Google Scholar
• •Well-reasoned prospective case-control study that estimates the level of maternal serotype Ia-specific antibody required to protect neonates against early onset infection caused by this serotype.
   Google Scholar
• Kasper DL, Paoletti LC, Wessels MR, et al. Immune response to Type III group B streptococcal polysaccharide—tetanus toxoid conjugate vaccine. J. Clin. Invest. 98,2308–2314 (1996).
   PubMed Web of Science ®Google Scholar
• Cheng Q, Carlson B, Pillai S, et al. Antibody against surface-bound C5a peptidase is opsonic and initiates macrophage killing of group B streptococci. Infect. Immun. 69, 2302–2308 (2001).
   PubMed Web of Science ®Google Scholar
• Shen X, Lagergard T, Yang Y, et al. Preparation and preclinical evaluation of experimental group B Streptococcus Type III polysaccharide—cholera toxin B subunit conjugate vaccine for intranasal immunization. Vaccine 19,850–861 (2001).
   Web of Science ®Google Scholar
• Larsson C, Holmgren J, Lindahl G, Bergquist C. Intranasal immunization of mice with group B streptococcal protein Rib and cholera toxin B subunit confers protection against lethal infection. Infect. Immun. 72,1184–1187 (2004).
   PubMed Web of Science ®Google Scholar
• •Very interesting paper on mucosal immunization.
   Google Scholar
• Moore MR, Schrag SJ, Schuchat A. Effects of intrapartum antimicrobial prophylaxis for prevention of group-B streptococcal disease on the incidence and ecology of early onset neonatal sepsis. Lancet Infect. Dis. 3,201–213 (2003).
   PubMed Web of Science ®Google Scholar
• ••Excellent paper reviewing the potentialassociations between intrapartum antimicrobial prophylaxis and changes in the causes of neonatal early onset sepsis.
   Google Scholar
• Schuchat A. Group B streptococcal disease: from trials and tribulations to triumph and trepidation. Clin. Infect. Dis. 33,751–756 (2001).
   PubMed Web of Science ®Google Scholar
• •Excellent and well-written overview highlighting the most important developments during the last two decades as well as the most recent advances in the treatment of GBS.
   Google Scholar